DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0153402 A1 Pompeius Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0153402 A1 Pompeius Et Al US 2005O1534O2A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0153402 A1 Pompeius et al. (43) Pub. Date: Jul. 14, 2005 (54) CORYNEBACTERIUM GLUTAMICUM Jul. 8, 1999 (DE)........................................ 1993.1420.9 GENES ENCODING REGULATORY Jul. 9, 1999 (DE). ... 199321. 22.1 PROTEINS Jul. 9, 1999 (DE) 19932.128.0 Jul. 9, 1999 (DE) 19932.134.5 (75) Inventors: Markus Pompeius, Waldsee (DE); Jul. 9, 1999 (DE). ... 19932206.6 Burkhard Kroger, Limburgerhof (DE); Jul. 9, 1999 (DE) 199322O7.4 Hartwig Schroder, Nubloch (DE); Jul. 14, 1999 (DE) 1993.30O3.4 Oskar Zelder, Speyer (DE); Gregor Aug. 31, 1999 (DE). ... 1994.1390.8 Haberhauer, Limburgerhof (DE) Sep. 3, 1999 (DE). 19942O882 Sep. 3, 1999 (DE)........................................ 19942124.2 Correspondence Address: LAHIVE & COCKFIELD, LLP. Publication Classification 28 STATE STREET BOSTON, MA 02109 (US) (51) Int. Cl. ............................ C12P 13/04; C12O 1/68; C07H 21/04; C12N 9/00; (73) Assignee: BASF AG, Ludwigshafen (DE) C12N 1/21; C12N 15/74 (21) Appl. No.: 11/006,098 (52) U.S. Cl. ............................. 435/106; 435/6; 435/69.1; 435/183; 435/320.1; 435/252.3; (22) Filed: Dec. 6, 2004 536/23.2 Related U.S. Application Data (57) ABSTRACT (63) Continuation of application No. 09/602,874, filed on Jun. 23, 2000, now abandoned. Isolated nucleic acid molecules, designated MR nucleic acid molecules, which encode novel MR proteins from Coryne (60) Provisional application No. 60/141,031, filed on Jun. bacterium glutamicum are described. The invention also 25, 1999. Provisional application No. 60/142,690, provides antisense nucleic acid molecules, recombinant filed on Jul. 1, 1999. Provisional application No. expression vectors containing MR nucleic acid molecules, 60/151,251, filed on Aug. 27, 1999. and host cells into which the expression vectors have been introduced. The invention still further provides isolated MR (30) Foreign Application Priority Data proteins, mutated MR proteins, fusion proteins, antigenic peptides and methods for the improvement of production of Jul. 1, 1999 (DE)........................................ 19930476.9 a desired compound from C. glutamicum based on genetic Jul. 8, 1999 (DE)........................................ 19931419.5 engineering of MR genes in this organism. US 2005/O153402 A1 Jul. 14, 2005 CORYNEBACTERIUM GLUTAMICUM GENES molecules of the invention, therefore, can be used to identify ENCODING REGULATORY PROTEINS microorganisms which can be used to produce fine chemi cals, e.g., by fermentation processes. Modulation of the RELATED APPLICATIONS expression of the MR nucleic acids of the invention, or modification of the sequence of the MR nucleic acid mol 0001. This application claims priority to U.S. Provisional ecules of the invention, can be used to modulate the pro Patent Application No. 60/141,031, filed Jun. 25, 1999, U.S. duction of one or more fine chemicals from a microorganism Provisional Patent Application No. 60/142,690, filed Jul. 1, (e.g., to improve the yield or production of one or more fine 1999, and also to U.S. Provisional Patent Application No. chemicals from a Corynebacterium or Brevibacterium spe 60/151,251, filed Aug. 27, 1999. This application also claims priority to German Patent Application No. 19930476.9, filed cies). Jul. 1, 1999, German Patent Application No. 19931419.5, 0005. The MR nucleic acids of the invention may also be filed Jul. 8, 1999, German Patent Application No. 1993 used to identify an organism as being Corynebacterium 1420.9, filed Jul. 8, 1999, German Patent Application No. glutamicum or a close relative thereof, or to identify the 19932122.1, filed Jul. 9, 1999, German Patent Application presence of C. glutamicum or a relative thereof in a mixed No. 19932128.0, filed Jul. 9, 1999, German Patent Appli population of microorganisms. The invention provides the cation No. 19932.134.5, filed Jul. 9, 1999, German Patent nucleic acid Sequences of a number of C. glutamicum genes, Application No. 19932206.6, filed Jul. 9, 1999, German by probing the extracted genomic DNA of a culture of a Patent Application No. 199322074, filed Jul. 9, 1999, unique or mixed population of microorganisms under Strin German Patent Application No. 19933003.4, filed Jul. 14, gent conditions with a probe Spanning a region of a C. 1999, German Patent Application No. 1994.1390.8, filed glutamicum gene which is unique to this organism, one can Aug. 31, 1999, German Patent Application No. 19942088.2, ascertain whether this organism is present. Although filed Sep. 3, 1999, and German Patent Application No. Corynebacterium glutamicum itself is nonpathogenic, it is 199421242, filed Sep. 3, 1999. The entire contents of all of related to species pathogenic in humans, Such as Coryne the aforementioned applications are hereby expressly incor bacterium diphtheriae (the causative agent of diphtheria); porated herein by this reference. the detection of Such organisms is of Significant clinical relevance. BACKGROUND OF THE INVENTION 0006. The MR nucleic acid molecules of the invention 0002 Certain products and by-products of naturally-oc may also serve as reference points for mapping of the C. curring metabolic processes in cells have utility in a wide glutamicum genome, or of genomes of related organisms. array of industries, including the food, feed, cosmetics, and Similarly, these molecules, or variants or portions thereof, pharmaceutical industries. These molecules, collectively may serve as markers for genetically engineered Coryne termed fine chemicals, include organic acids, both protei bacterium or Brevibacterium species. e.g. The MR proteins nogenic and non-proteinogenic amino acids, nucleotides and encoded by the novel nucleic acid molecules of the inven nucleosides, lipids and fatty acids, diols, carbohydrates, tion are capable of, for example, performing a function aromatic compounds, Vitamins and cofactors, and enzymes. involved in the transcriptional, translational, or posttransla Their production is most conveniently performed through tional regulation of proteins important for the normal meta the large-scale culture of bacteria developed to produce and bolic functioning of cells. Given the availability of cloning Secrete large quantities of one or more desired molecules. vectors for use in Corynebacterium glutamicum, Such as One particularly useful organism for this purpose is Coryne those disclosed in Sinskey et al., U.S. Pat. No. 4,649,119, bacterium glutamicum, a gram positive, nonpathogenic bac and techniques for genetic manipulation of C. glutamicum terium. Through Strain Selection, a number of mutant Strains and the related Brevibacterium species (e.g., lactofermen have been developed which produce an array of desirable tum) (Yoshihama et al., J. Bacteriol. 162: 591-597 (1985); compounds. However, Selection of Strains improved for the Katsumata et al., J. Bacteriol. 159: 306-311 (1984); and production of a particular molecule is a time-consuming and Santamaria et al., J. Gen. Microbiol. 130: 2237-2246 difficult process. (1984)), the nucleic acid molecules of the invention may be utilized in the genetic engineering of this organism to make SUMMARY OF THE INVENTION it a better or more efficient producer of one or more fine chemicals. 0003. The invention provides novel bacterial nucleic acid 0007. This improved yield, production and/or efficiency molecules which have a variety of uses. These uses include of production of a fine chemical may be due to a direct effect the identification of microorganisms which can be used to of manipulation of a gene of the invention, or it may be due produce fine chemicals, the modulation of fine chemical to an indirect effect of Such manipulation. Specifically, production in C. glutamicum or related bacteria, the typing alterations in C. glutamicum MR proteins which normally or identification of C. glutamicum or related bacteria, as regulate the yield, production and/or efficiency of produc reference points for mapping the C. glutamicum genome, tion of a fine chemical metabolic pathways may have a direct and as markers for transformation. These novel nucleic acid impact on the overall production or rate of production of one molecules encode proteins, referred to herein as metabolic or more of these desired compounds from this organism. regulatory (MR) proteins. Alterations in the proteins involved in these metabolic 0004 C. glutamicum is a gram positive, aerobic bacte pathways may also have an indirect impact on the yield, rium which is commonly used in industry for the large-scale production and/or efficiency of production of a desired fine production of a variety of fine chemicals, and also for the chemical. Regulation of metabolism is necessarily complex, degradation of hydrocarbons (Such as in petroleum spills) and the regulatory mechanisms governing different path and for the oxidation of terpenoids. The MR nucleic acid ways may interSect at multiple points Such that more than US 2005/O153402 A1 Jul. 14, 2005 one pathway can be rapidly adjusted in accordance with a bolic pathway proteins (MR), which are capable of, for particular cellular event. This enables the modification of a example, performing an enzymatic Step involved in the regulatory protein for one pathway to have an impact on the transcriptional, translational, or posttranslational regulation regulation of many other pathways as well, Some of which of metabolic pathways in C. glutamicum. Nucleic acid may be involved in the biosynthesis or degradation of a molecules
Load more

Recommended publications
  • Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers
    Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers. by Kelly Kennaley A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Molecular and Cellular Pathology) in the University of Michigan 2019 Doctoral Committee: Associate Professor Zaneta Nikolovska-Coleska, Co-Chair Adjunct Associate Professor Scott A. Tomlins, Co-Chair Associate Professor Eric R. Fearon Associate Professor Alexey I. Nesvizhskii Kelly R. Kennaley [email protected] ORCID iD: 0000-0003-2439-9020 © Kelly R. Kennaley 2019 Acknowledgements I have immeasurable gratitude for the unwavering support and guidance I received throughout my dissertation. First and foremost, I would like to thank my thesis advisor and mentor Dr. Scott Tomlins for entrusting me with a challenging, interesting, and impactful project. He taught me how to drive a project forward through set-backs, ask the important questions, and always consider the impact of my work. I’m truly appreciative for his commitment to ensuring that I would get the most from my graduate education. I am also grateful to the many members of the Tomlins lab that made it the supportive, collaborative, and educational environment that it was. I would like to give special thanks to those I’ve worked closely with on this project, particularly Dr. Moloy Goswami for his mentorship, Lei Lucy Wang, Dr. Sumin Han, and undergraduate students Bhavneet Singh, Travis Weiss, and Myles Barlow. I am also grateful for the support of my thesis committee, Dr. Eric Fearon, Dr. Alexey Nesvizhskii, and my co-mentor Dr. Zaneta Nikolovska-Coleska, who have offered guidance and critical evaluation since project inception.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Product Datasheet PBDC1 Antibody NBP1-82657
    Product Datasheet PBDC1 Antibody NBP1-82657 Unit Size: 0.1 ml Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP1-82657 Updated 6/7/2021 v.20.1 Earn rewards for product reviews and publications. Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBP1-82657 Page 1 of 4 v.20.1 Updated 6/7/2021 NBP1-82657 PBDC1 Antibody Product Information Unit Size 0.1 ml Concentration Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services. Storage Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. Clonality Polyclonal Preservative 0.02% Sodium Azide Isotype IgG Purity Immunogen affinity purified Buffer PBS (pH 7.2) and 40% Glycerol Product Description Host Rabbit Gene ID 51260 Gene Symbol PBDC1 Species Human Reactivity Notes Immunogen displays the following percentage of sequence identity for non- tested species: Mouse (83%), Rat (85%) Immunogen This antibody was developed against Recombinant Protein corresponding to amino acids: EVYYKLISSVDPQFLKLTKVDDQIYSEFRKNFETLRIDVLDPEELKSESAKEKWR PFCLKFNGIVEDFNYGTLLRLDCSQGYTEENTIFAPRIQFFAIEIARNREGYNKAV YISVQDKEGEKGVNNGGEKRADSGEEENTKNGGEK Product Application Details Applications Western Blot, Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin Recommended Dilutions Western Blot 0.04 - 0.4 ug/ml,
    [Show full text]
  • MMP-25 Metalloprotease Regulates Innate Immune Response Through NF- Κb Signaling Clara Soria-Valles, Ana Gutiérrez-Fernández, Fernando G
    MMP-25 Metalloprotease Regulates Innate Immune Response through NF- κB Signaling Clara Soria-Valles, Ana Gutiérrez-Fernández, Fernando G. Osorio, Dido Carrero, Adolfo A. Ferrando, Enrique Colado, This information is current as M. Soledad Fernández-García, Elena Bonzon-Kulichenko, of September 27, 2021. Jesús Vázquez, Antonio Fueyo and Carlos López-Otín J Immunol 2016; 197:296-302; Prepublished online 3 June 2016; doi: 10.4049/jimmunol.1600094 Downloaded from http://www.jimmunol.org/content/197/1/296 Supplementary http://www.jimmunol.org/content/suppl/2016/06/01/jimmunol.160009 Material 4.DCSupplemental http://www.jimmunol.org/ References This article cites 41 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/197/1/296.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 27, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology MMP-25 Metalloprotease Regulates Innate Immune Response through NF-kB Signaling Clara Soria-Valles,* Ana Gutie´rrez-Ferna´ndez,* Fernando G.
    [Show full text]
  • Product Datasheet Cxorf26 Recombinant Protein Antigen NBP1
    Product Datasheet CXorf26 Recombinant Protein Antigen NBP1-82657PEP Unit Size: 0.1 ml Store at -20C. Avoid freeze-thaw cycles. Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP1-82657PEP Updated 11/3/2016 v.20.1 Earn rewards for product reviews and publications. Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBP1-82657PEP Page 1 of 2 v.20.1 Updated 11/3/2016 NBP1-82657PEP CXorf26 Recombinant Protein Antigen Product Information Unit Size 0.1 ml Concentration Please see the vial label for concentration. If unlisted please contact technical services. Storage Store at -20C. Avoid freeze-thaw cycles. Preservative No Preservative Purity >80% by SDS-PAGE and Coomassie blue staining Buffer PBS and 1M Urea, pH 7.4. Target Molecular Weight 34 kDa Product Description Description A recombinant protein antigen with a N-terminal His6-ABP tag corresponding to human PBDC1. Source: E.coli Amino Acid Sequence: EVYYKLISSVDPQFLKLTKVDDQIYSEFRKNFETLRIDVLDPEELKSESAKEKWR PFCLKFNGIVEDFNYGTLLRLDCSQGYTEENTIFAPRIQFFAIEIARNREGYNKAV YISVQDKEGEKGVNNGGEKRADSGEEENTKNGGEK Gene ID 51260 Gene Symbol PBDC1 Species Human Product Application Details Applications Antibody Competition Recommended Dilutions Antibody Competition 10 - 100 molar excess Application Notes This peptide is useful as a blocking peptide for NBP1-82657.Protein was purified by IMAC chromatography. The expected concentration is greater than 0.5 mg/ml. This product is produced on demand, estimated
    [Show full text]
  • PRODUCT SPECIFICATION Anti-PBDC1 Product
    Anti-PBDC1 Product Datasheet Polyclonal Antibody PRODUCT SPECIFICATION Product Name Anti-PBDC1 Product Number HPA003155 Gene Description polysaccharide biosynthesis domain containing 1 Clonality Polyclonal Isotype IgG Host Rabbit Antigen Sequence Recombinant Protein Epitope Signature Tag (PrEST) antigen sequence: EVYYKLISSVDPQFLKLTKVDDQIYSEFRKNFETLRIDVLDPEELKSESA KEKWRPFCLKFNGIVEDFNYGTLLRLDCSQGYTEENTIFAPRIQFFAIEI ARNREGYNKAVYISVQDKEGEKGVNNGGEKRADSGEEENTKNGGEK Purification Method Affinity purified using the PrEST antigen as affinity ligand Verified Species Human Reactivity Recommended IHC (Immunohistochemistry) Applications - Antibody dilution: 1:200 - 1:500 - Retrieval method: HIER pH6 WB (Western Blot) - Working concentration: 0.04-0.4 µg/ml ICC-IF (Immunofluorescence) - Fixation/Permeabilization: PFA/Triton X-100 - Working concentration: 0.25-2 µg/ml Characterization Data Available at atlasantibodies.com/products/HPA003155 Buffer 40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative. Concentration Lot dependent Storage Store at +4°C for short term storage. Long time storage is recommended at -20°C. Notes Gently mix before use. Optimal concentrations and conditions for each application should be determined by the user. For protocols, additional product information, such as images and references, see atlasantibodies.com. Product of Sweden. For research use only. Not intended for pharmaceutical development, diagnostic, therapeutic or any in vivo use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB. Warranty: The products supplied by Atlas Antibodies are warranted to meet stated product specifications and to conform to label descriptions when used and stored properly. Unless otherwise stated, this warranty is limited to one year from date of sales for products used, handled and stored according to Atlas Antibodies AB's instructions.
    [Show full text]
  • Engineered Type 1 Regulatory T Cells Designed for Clinical Use Kill Primary
    ARTICLE Acute Myeloid Leukemia Engineered type 1 regulatory T cells designed Ferrata Storti Foundation for clinical use kill primary pediatric acute myeloid leukemia cells Brandon Cieniewicz,1* Molly Javier Uyeda,1,2* Ping (Pauline) Chen,1 Ece Canan Sayitoglu,1 Jeffrey Mao-Hwa Liu,1 Grazia Andolfi,3 Katharine Greenthal,1 Alice Bertaina,1,4 Silvia Gregori,3 Rosa Bacchetta,1,4 Norman James Lacayo,1 Alma-Martina Cepika1,4# and Maria Grazia Roncarolo1,2,4# Haematologica 2021 Volume 106(10):2588-2597 1Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 2Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 3San Raffaele Telethon Institute for Gene Therapy, Milan, Italy and 4Center for Definitive and Curative Medicine, Stanford School of Medicine, Stanford, CA, USA *BC and MJU contributed equally as co-first authors #AMC and MGR contributed equally as co-senior authors ABSTRACT ype 1 regulatory (Tr1) T cells induced by enforced expression of interleukin-10 (LV-10) are being developed as a novel treatment for Tchemotherapy-resistant myeloid leukemias. In vivo, LV-10 cells do not cause graft-versus-host disease while mediating graft-versus-leukemia effect against adult acute myeloid leukemia (AML). Since pediatric AML (pAML) and adult AML are different on a genetic and epigenetic level, we investigate herein whether LV-10 cells also efficiently kill pAML cells. We show that the majority of primary pAML are killed by LV-10 cells, with different levels of sensitivity to killing. Transcriptionally, pAML sensitive to LV-10 killing expressed a myeloid maturation signature.
    [Show full text]
  • Allele-Specific Non-CG DNA Methylation Marks Domains Of
    Allele-specific non-CG DNA methylation marks domains PNAS PLUS of active chromatin in female mouse brain Christopher L. Keowna, Joel B. Berletchb, Rosa Castanonc, Joseph R. Neryc, Christine M. Distecheb,d, Joseph R. Eckerc,e, and Eran A. Mukamela,1 aDepartment of Cognitive Science, University of California, San Diego, CA 92037; bDepartment of Pathology, University of Washington, Seattle, WA 98195; cGenomic Analysis Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037; dDepartment of Medicine, University of Washington, Seattle, WA 98195; and eHoward Hughes Medical Institute, The Salk Institute for Biological Studies, La Jolla, CA 92037 Edited by Paul D. Soloway, Cornell University, Ithaca, NY, and accepted by Editorial Board Member Andrew G. Clark December 20, 2016 (received for review July 21, 2016) DNA methylation at gene promoters in a CG context is associated correlated with high or low levels of DNA methylation at CG with transcriptional repression, including at genes silenced on the dinucleotides (mCG) in promoter regions, respectively (10). How- inactive X chromosome in females. Non-CG methylation (mCH) is a ever, different epigenetic profiles may be associated with XCI and distinct feature of the neuronal epigenome that is differentially escape from XCI in the brain because the DNA methylation distributed between males and females on the X chromosome. landscape of neurons is distinct from other cell types. In particular, However, little is known about differences in mCH on the active neurons accumulate methylation at millions of genomic cytosines in (Xa) and inactive (Xi) X chromosomes because stochastic CA and CT dinucleotides during postnatal brain development be- X-chromosome inactivation (XCI) confounds allele-specific epige- ginning at 1 wk of age in mice (6, 11).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,892,798 B2 Pompejus Et Al
    US007892798B2 (12) United States Patent (10) Patent No.: US 7,892,798 B2 Pompejus et al. (45) Date of Patent: Feb. 22, 2011 (54) NUCLEICACID MOLECULES ENCODING (56) References Cited METABOLC REGULATORY PROTEINS U.S. PATENT DOCUMENTS FROM CORYNEBACTERIUM GLUTAMICUM, USEFUL FOR INCREASING THE 3,729,381 A 4, 1973 Nakayama et al. PRODUCTION OF METHONONE BY A 2005. O153402 A1 7/2005 Pompeius et al. MCROORGANISM FOREIGN PATENT DOCUMENTS (75) Inventors: Markus Pompeius, Freinsheim (DE); EP 1108790 A2 6, 2001 Burkhard Kröger, Limburgerhof (DE); EP 1108790 A2 * 6, 2001 Hartwig Schröder, Nussloch (DE); JP 50-31092 3, 1975 Oskar Zelder, Speyer (DE); Gregor WO WO-O2/O97096 A2 12/2002 Haberhauer, Limburgerhof (DE); OTHER PUBLICATIONS Stefan Haefner, Ludwigshafen (DE); Seffernicket al. J. Bateriol., vol. 183, pp. 2405-2410, 2001.* Corrinna Klopprogge, Ludwigshafen Branden et al. “Introduction to Protein Structure', Garland Publish (DE) ing Inc., New York, 1991, p. 247.* Witkowski et al., Biochemistry 38: 11643-11650, 1999.* (73) Assignee: Evonik Degussa GmbH, Essen (DE) Renna et al., J Bacteriol 175:3863-3875, 1993.* Dictionary definition of “positively at Encarta.com, last viewed on (*) Notice: Subject to any disclaimer, the term of this Jan. 16, 2008, 2 pages.* patent is extended or adjusted under 35 Kolmar et al., EMBO.J. 14:3895-3904, 1995.* U.S.C. 154(b) by 239 days. Hwang et al., J. Bacteriol. 184:1277-1286, 2002.* Belfaiza, J. et al. “Direct Sulfhydrylation for Methionine (21) Appl. No.: 10/307,138 Biosynthesis in Leptospira meyeri,’ Journal of Bacteriology, vol. 180(2):250-255 (1998). (22) Filed: Nov.
    [Show full text]
  • Cxorf26 (PBDC1) Mouse Monoclonal Antibody [Clone ID: OTI1F3] Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA503238 CXorf26 (PBDC1) Mouse Monoclonal Antibody [Clone ID: OTI1F3] Product data: Product Type: Primary Antibodies Clone Name: OTI1F3 Applications: FC, IF, WB Recommended Dilution: WB 1:500, IF 1:100, FLOW 1:100 Reactivity: Human, Mouse, Rat Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Full length human recombinant protein of human CXorf26(NP_057584) produced in HEK293T cell. Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 0.24 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 25.9 kDa Gene Name: polysaccharide biosynthesis domain containing 1 Database Link: NP_057584 Entrez Gene 51260 Human Q9BVG4 Synonyms: CXorf26 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 CXorf26 (PBDC1) Mouse Monoclonal Antibody [Clone ID: OTI1F3] – TA503238 Product images: HEK293T cells were transfected with the pCMV6- ENTRY control (Left lane) or pCMV6-ENTRY CXorf26 ([RC200095], Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CXorf26. Positive lysates [LY413940] (100ug) and [LC413940] (20ug) can be purchased separately from OriGene.
    [Show full text]
  • The Zinc Transporter Zip14 (Slc39a14) Affects Beta-Cell Function
    www.nature.com/scientificreports OPEN The zinc transporter Zip14 (SLC39a14) afects Beta-cell Function: Proteomics, Gene Received: 7 January 2019 Accepted: 24 May 2019 expression, and Insulin secretion Published: xx xx xxxx studies in INS-1E cells Trine Maxel1, Kamille Smidt2, Charlotte C. Petersen1, Bent Honoré1, Anne K. Christensen1, Per B. Jeppesen2,3, Birgitte Brock4, Jørgen Rungby5, Johan Palmfeldt2,6 & Agnete Larsen1 Insulin secretion from pancreatic beta-cells is dependent on zinc ions as essential components of insulin crystals, zinc transporters are thus involved in the insulin secretory process. Zip14 (SLC39a14) is a zinc importing protein that has an important role in glucose homeostasis. Zip14 knockout mice display hyperinsulinemia and impaired insulin secretion in high glucose conditions. Endocrine roles for Zip14 have been established in adipocytes and hepatocytes, but not yet confrmed in beta- cells. In this study, we investigated the role of Zip14 in the INS-1E beta-cell line. Zip14 mRNA was upregulated during high glucose stimulation and Zip14 silencing led to increased intracellular insulin content. Large-scale proteomics showed that Zip14 silencing down-regulated ribosomal mitochondrial proteins, many metal-binding proteins, and others involved in oxidative phosphorylation and insulin secretion. Furthermore, proliferation marker Mki67 was down-regulated in Zip14 siRNA-treated cells. In conclusion, Zip14 gene expression is glucose sensitive and silencing of Zip14 directly afects insulin processing in INS-1E beta-cells. A link between Zip14 and ribosomal mitochondrial proteins suggests altered mitochondrial RNA translation, which could disturb mitochondrial function and thereby insulin secretion. This highlights a role for Zip14 in beta-cell functioning and suggests Zip14 as a future pharmacological target in the treatment of beta-cell dysfunction.
    [Show full text]
  • Fatty Acid Metabolism Driven Mitochondrial Bioenergetics Promotes Advanced Developmental Phenotypes in Human Induced Pluripotent Stem Cell Derived Cardiomyocytes
    Fatty acid metabolism driven mitochondrial bioenergetics promotes advanced developmental phenotypes in human induced pluripotent stem cell derived cardiomyocytes Chrishan J.A. Ramachandra1,a,b, Ashish Mehta1,c, Philip Wonga,b,d,e*, K.P. Myu Mai Jaa, Regina Fritsche-Danielsonf, Ratan V. Bhatg, Derek J. Hausenloya,b,h,i,j, Jean-Paul Kovalikb and Winston Shima,b,k* aNational Heart Research Institute Singapore, National Heart Centre Singapore bCardiovascular & Metabolic Disorders Program, Duke-NUS Medical School, Singapore cPSC and Phenotyping Laboratory, Victor Chang Cardiac Research Institute, Sydney, Australia dDepartment of Cardiology, National Heart Centre Singapore eSchool of Materials Science and Engineering, Nanyang Technological University, Singapore fCardiovascular and Metabolic Disease Innovative Medicines and Early Development Unit, AstraZeneca Research and Development, Gothenburg, Sweden gStrategy and External Innovation Department, AstraZeneca, Gothenburg, Sweden hThe Hatter Cardiovascular Institute, University College London, United Kingdom iBarts Heart Centre, St Barthlomew’s Hospital, London, United Kingdom jYong Loo Lin School of Medicine, National University of Singapore kHealth and Social Sciences Cluster, Singapore Institute of Technology 1Both authors contributed equally Running title: Cardiomyocyte metabolism and bioenergetics *Corresponding authors: Philip Wong National Heart Centre Singapore, 5 Hospital Drive, Singapore 169609 Email: [email protected]; Phone: +65 6704 8964; Fax: +65 6844 9053 Winston Shim
    [Show full text]